← Alexandria Real Estate Equities overview

Alexandria Real Estate Equities vs BXP: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Alexandria Real Estate Equities Inc (ARE)

Q3 2026
▲2▼1

Alexandria's cash flow weakens as it shores up its balance sheet

  • Big pharma lab demand still real Alexandria handed Bristol Myers Squibb a 427,000-square-foot San Diego research hub. A global drugmaker taking that much purpose-built lab space shows large tenants still want Alexandria's campuses, supporting leasing and long-term rent.

    Shows the demand side of the business is still working, a real support for the stock.

  • Earnings quality is deteriorating Q2 adjusted funds from operations (a REIT's main profit gauge) fell to $1.73 a share from $2.33, revenue dropped, same-property net operating income fell 10.6%, and occupancy slipped to 86.9%. Even with more leasing, the cash the buildings produce is shrinking.

    The core profit and cash-flow decline is the main force weighing on the shares.

  • Debt load grows while credit access improves Alexandria priced $1 billion of 7.25% junior notes, adding interest cost, and leverage is 7.0x net debt to EBITDA, above its own 5.6x-6.2x target. It also replaced its credit line with a bigger $5 billion facility maturing to 2032, giving flexibility to sell assets and pay down debt.

    Captures both the balance-sheet strain and the refinancing that buys time to fix it.

  • A value investor steps in Baron Real Estate Income Fund disclosed a new stake, saying life science real estate is stabilizing after years of weak demand and excess supply, and expecting growth to turn up as Alexandria sells properties and buys back its beaten-down shares.

    Shows outside investors see the depressed price as an opportunity, a counterweight to the weak results.

August 2026
▲2▼1

Alexandria's cash flow weakens as it shores up its balance sheet

  • Big pharma lab demand still real Alexandria handed Bristol Myers Squibb a 427,000-square-foot San Diego research hub. A global drugmaker taking that much purpose-built lab space shows large tenants still want Alexandria's campuses, supporting leasing and long-term rent.

    Shows the demand side of the business is still working, a real support for the stock.

  • Earnings quality is deteriorating Q2 adjusted funds from operations (a REIT's main profit gauge) fell to $1.73 a share from $2.33, revenue dropped, same-property net operating income fell 10.6%, and occupancy slipped to 86.9%. Even with more leasing, the cash the buildings produce is shrinking.

    The core profit and cash-flow decline is the main force weighing on the shares.

  • Debt load grows while credit access improves Alexandria priced $1 billion of 7.25% junior notes, adding interest cost, and leverage is 7.0x net debt to EBITDA, above its own 5.6x-6.2x target. It also replaced its credit line with a bigger $5 billion facility maturing to 2032, giving flexibility to sell assets and pay down debt.

    Captures both the balance-sheet strain and the refinancing that buys time to fix it.

  • A value investor steps in Baron Real Estate Income Fund disclosed a new stake, saying life science real estate is stabilizing after years of weak demand and excess supply, and expecting growth to turn up as Alexandria sells properties and buys back its beaten-down shares.

    Shows outside investors see the depressed price as an opportunity, a counterweight to the weak results.

Latest
▲2▼1

Alexandria's cash flow weakens as it shores up its balance sheet

  • Big pharma lab demand still real Alexandria handed Bristol Myers Squibb a 427,000-square-foot San Diego research hub. A global drugmaker taking that much purpose-built lab space shows large tenants still want Alexandria's campuses, supporting leasing and long-term rent.

    Shows the demand side of the business is still working, a real support for the stock.

  • Earnings quality is deteriorating Q2 adjusted funds from operations (a REIT's main profit gauge) fell to $1.73 a share from $2.33, revenue dropped, same-property net operating income fell 10.6%, and occupancy slipped to 86.9%. Even with more leasing, the cash the buildings produce is shrinking.

    The core profit and cash-flow decline is the main force weighing on the shares.

  • Debt load grows while credit access improves Alexandria priced $1 billion of 7.25% junior notes, adding interest cost, and leverage is 7.0x net debt to EBITDA, above its own 5.6x-6.2x target. It also replaced its credit line with a bigger $5 billion facility maturing to 2032, giving flexibility to sell assets and pay down debt.

    Captures both the balance-sheet strain and the refinancing that buys time to fix it.

  • A value investor steps in Baron Real Estate Income Fund disclosed a new stake, saying life science real estate is stabilizing after years of weak demand and excess supply, and expecting growth to turn up as Alexandria sells properties and buys back its beaten-down shares.

    Shows outside investors see the depressed price as an opportunity, a counterweight to the weak results.

BXP, Inc. (BXP)

Q3 2026
▲3▼1

BXP beats Q2, raises FFO outlook, but refinancing costs rise

  • Q2 beat and raised FFO guidance BXP's Q2 funds from operations (a key REIT profit measure) beat estimates and rose 4.1% from a year ago. Occupancy improved and the company raised its full-year 2026 FFO outlook, signaling stronger operations than expected. This supports the stock because it shows the core business is performing better.

    This is the main positive fundamental driver for BXP's price this period.

  • Strong leasing activity and major tenant commitments BXP signed 106 leases covering 1.8 million square feet, including a 322,000-square-foot lease with Boston Dynamics and a 148,000-square-foot lease at 343 Madison Avenue. High leasing volume and big-name tenants reduce vacancy risk and support future rental income, which is positive for the stock.

    Leasing momentum directly affects future revenue and occupancy, a key value driver for office REITs.

  • $1.2 billion construction loan for 343 Madison Avenue BXP secured a $1.2 billion construction loan for its 343 Madison Avenue tower, covering a large part of the $2 billion project cost. The loan has a four-year term and an initial interest rate of SOFR plus 2.50%. This financing milestone reduces funding uncertainty and keeps the development on track, which is positive for the stock.

    This is a major capital event that de-risks a large development project.

  • New $700 million notes at 6.05% raise interest costs BXP priced $700 million of senior unsecured notes at 6.05% to help repay $1 billion of older 2.75% notes due 2026. The new debt carries a much higher interest rate, increasing annual interest expense by roughly $23 million. Higher financing costs weigh on earnings and are a negative for the stock.

    This is the main negative capital markets event this period, directly raising BXP's cost of debt.

August 2026
▲3▼1

BXP beats Q2, raises FFO outlook, but refinancing costs rise

  • Q2 beat and raised FFO guidance BXP's Q2 funds from operations (a key REIT profit measure) beat estimates and rose 4.1% from a year ago. Occupancy improved and the company raised its full-year 2026 FFO outlook, signaling stronger operations than expected. This supports the stock because it shows the core business is performing better.

    This is the main positive fundamental driver for BXP's price this period.

  • Strong leasing activity and major tenant commitments BXP signed 106 leases covering 1.8 million square feet, including a 322,000-square-foot lease with Boston Dynamics and a 148,000-square-foot lease at 343 Madison Avenue. High leasing volume and big-name tenants reduce vacancy risk and support future rental income, which is positive for the stock.

    Leasing momentum directly affects future revenue and occupancy, a key value driver for office REITs.

  • $1.2 billion construction loan for 343 Madison Avenue BXP secured a $1.2 billion construction loan for its 343 Madison Avenue tower, covering a large part of the $2 billion project cost. The loan has a four-year term and an initial interest rate of SOFR plus 2.50%. This financing milestone reduces funding uncertainty and keeps the development on track, which is positive for the stock.

    This is a major capital event that de-risks a large development project.

  • New $700 million notes at 6.05% raise interest costs BXP priced $700 million of senior unsecured notes at 6.05% to help repay $1 billion of older 2.75% notes due 2026. The new debt carries a much higher interest rate, increasing annual interest expense by roughly $23 million. Higher financing costs weigh on earnings and are a negative for the stock.

    This is the main negative capital markets event this period, directly raising BXP's cost of debt.

Latest
▲3▼1

BXP beats Q2, raises FFO outlook, but refinancing costs rise

  • Q2 beat and raised FFO guidance BXP's Q2 funds from operations (a key REIT profit measure) beat estimates and rose 4.1% from a year ago. Occupancy improved and the company raised its full-year 2026 FFO outlook, signaling stronger operations than expected. This supports the stock because it shows the core business is performing better.

    This is the main positive fundamental driver for BXP's price this period.

  • Strong leasing activity and major tenant commitments BXP signed 106 leases covering 1.8 million square feet, including a 322,000-square-foot lease with Boston Dynamics and a 148,000-square-foot lease at 343 Madison Avenue. High leasing volume and big-name tenants reduce vacancy risk and support future rental income, which is positive for the stock.

    Leasing momentum directly affects future revenue and occupancy, a key value driver for office REITs.

  • $1.2 billion construction loan for 343 Madison Avenue BXP secured a $1.2 billion construction loan for its 343 Madison Avenue tower, covering a large part of the $2 billion project cost. The loan has a four-year term and an initial interest rate of SOFR plus 2.50%. This financing milestone reduces funding uncertainty and keeps the development on track, which is positive for the stock.

    This is a major capital event that de-risks a large development project.

  • New $700 million notes at 6.05% raise interest costs BXP priced $700 million of senior unsecured notes at 6.05% to help repay $1 billion of older 2.75% notes due 2026. The new debt carries a much higher interest rate, increasing annual interest expense by roughly $23 million. Higher financing costs weigh on earnings and are a negative for the stock.

    This is the main negative capital markets event this period, directly raising BXP's cost of debt.